Eptifibatide
- Generic Name
- Eptifibatide
- Brand Names
- Integrilin, Eptifibatide Accord
- Drug Type
- Biotech
- CAS Number
- 188627-80-7
- Unique Ingredient Identifier
- NA8320J834
Overview
Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.
Background
Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.
Indication
For treatment of myocardial infarction and acute coronary syndrome.
Associated Conditions
- Acute Coronary Syndrome (ACS)
- Percutaneous Coronary Intervention (PCI)
Clinical Trials
FDA Approved Products
Eptifibatide
Manufacturer:Slate Run Pharmaceuticals, LLC
Route:INTRAVENOUS
Strength:0.75 mg in 1 mL
Approved: 2022/11/24
NDC:70436-027
Eptifibatide
Manufacturer:Mylan Institutional LLC
Route:INTRAVENOUS
Strength:2 mg in 1 mL
Approved: 2018/12/17
NDC:67457-629
Eptifibatide
Manufacturer:Mylan Institutional LLC
Route:INTRAVENOUS
Strength:0.75 mg in 1 mL
Approved: 2018/12/17
NDC:67457-631
Eptifibatide
Manufacturer:Slate Run Pharmaceuticals, LLC
Route:INTRAVENOUS
Strength:2 mg in 1 mL
Approved: 2022/11/24
NDC:70436-026
Eptifibatide
Manufacturer:Hainan Poly Pharm. Co., Ltd.
Route:INTRAVENOUS
Strength:0.75 mg in 1 mL
Approved: 2021/04/27
NDC:14335-071
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath